Key result
Endothelin receptor antagonists reduce blood pressure in resistant hypertension and improve proteinuria in chronic kidney disease, though side effects require further elucidation.
Why the study?
Do endothelin receptor antagonists reduce blood pressure and proteinuria in patients with resistant hypertension and chronic kidney disease?
Do endothelin receptor antagonists reduce blood pressure and proteinuria in patients with resistant hypertension and chronic kidney disease?
Endothelin receptor antagonists represent a promising therapeutic target for resistant hypertension and CKD, though clinical application is currently limited by side effects such as fluid retention.
No takes yet. Share an insight, caveat, or question.
Endothelin blockade may aid BP and proteinuria control in resistant hypertension with CKD; leaves open RCTs to confirm net benefit amid fluid retention risks.
Donald E. Kohan (2010) conducted a review in Hypertension and chronic kidney disease. Endothelin receptor antagonists was evaluated. Endothelin receptor antagonists reduce blood pressure in resistant hypertension and improve proteinuria in chronic kidney disease, though side effects require further elucidation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: